ITM Isotopen Technologien München AG (ITM), a specialized group of radiopharmaceutical companies, announced today that it has received the Pharma Trend Award 2018 "Most Innovative Product" in the start-up category. An interdisciplinary jury of six pharma representatives evaluated the submissions from start-up companies in biotechnology, medical engineering and digital health industries. The 19th edition of the awards ceremony took place on September 18, 2018, in the Deutsches Museum (German Museum) in Munich. The “Best Pharmaceutical Companies in Germany” ranking was also announced at the event in conjunction with the Pharma Trend “Image and Innovation Award”.
The ranking is based on the survey data collected by Pharma Trend, which has been conducting annual surveys among doctors in Germany in the Rx category (prescription drugs) since 2000. As of 2018, it now also surveys 900 doctors and pharmacists in the OTC (pharmacists) and orphan drugs (clinicians) categories. In addition, 600 patients were surveyed in the OTC category. The expansion of the Pharma Trend survey enables pharmaceutical companies to be evaluated by their most important stakeholders (doctors, pharmacists and patients) in Germany in terms of innovation and sustainability. The respondents assess the pharmaceutical companies with regard to the quality of their marketing and sales, the quality of their products and services, innovation, affordability, transparency,
responsibility, ethical practices, management quality and business success.
The criteria of patient benefit, innovation, efficient patient care and integration in the German statutory insurance scheme were particularly decisive for the jury in the assessment of the products and projects submitted for the start-ups category, in which ITM took part.
Steffen Schuster, Chief Executive Officer of ITM, said, "We are delighted to receive the ‘Most Innovative Product’ award at Pharma Trend 2018. Winning first place highlights our successful work in the development and preparation of a new generation of targeted cancer diagnostics and treatments. Targeted Radionuclide Therapy is increasingly seen as a promising treatment option for cancer and has already been used successfully for many years under compassionate use. We are confident that our lead candidate Solucin® for the treatment of neuroendocrine tumors, which is currently in phase III clinical trial, will be able to confirm these excellent results and will obtain approval as one of the world’s first therapeutic radiopharmaceuticals. With our Targeted Radionuclide Therapy, we want to make a significant contribution to improve outcomes and quality of life for cancer patients.”
– End –
About ITM
ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of novel, first-in-class medical radionuclides and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers or bone metastases. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side-effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
For more information about ITM, please visit: www.itm.ag
Contact:
Nicola Scharrer
Head of Marketing
Phone: +49 89 3298986-16
Email: Nicola.Scharrer(at)itm.ag
Media Contact: WE Communications
Sebastian Klein
Senior Account Executive
Phone: +49 89 628175-46
Email: ITM_AG(at)we-worldwide.com
ITM Isotopen Technologien München AG
Chairman of the Supervisory Board - Udo J. Vetter, Executive Board - Steffen Schuster (Chairman), Thomas Dürre
Registered Office of the Company - Lichtenbergstr. 1, 85748 Garching – Commercial Register Munich - HRB 154944
